1992
DOI: 10.1007/bf00266355
|View full text |Cite
|
Sign up to set email alerts
|

Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects

Abstract: The effects of single dose (20 mg) and short-term (20 mg/day for 8 days) oral treatment with omeprazole on the pharmacokinetics and effects of oral nifedipine (10 mg capsule) and on gastric pH have been investigated in a randomized, double-blind, placebo-controlled cross-over study in 10 non-smoking healthy male subjects. The single dose of omeprazole had no significant effect on any pharmacokinetic parameter of nifedipine, nor on gastric pH, or blood pressure or heart rate. Short-term omeprazole treatment inc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
49
2
1

Year Published

1996
1996
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 58 publications
(53 citation statements)
references
References 30 publications
1
49
2
1
Order By: Relevance
“…Although 9 of 15, or 60%, of the clinical noninducers examined also activated PXR/CYP3A in DPX2 cells (Table 3), these same agents give induction of CYP3A4 mRNA in hepatocytes and other model systems . Among the noninducers, rosiglitazone promoted PXR activation in vitro only at concentrations exceeding 25 M, which far surpasses the C max of 1.4 M in vivo (Fahmi et al, 2008a), whereas omeprazole activated PXR at levels (Ͼ10 M) that exceeded the C max of 0.68 M (Soons et al, 1992). Despite eliciting substantial PXR activation (E max Ͼ9-fold), neither leflunomide nor omeprazole increased CYP3A-mediated luciferin-IPA metabolism in DPX2 cells (Fig.…”
Section: Dpx2 Cells For Predicting Ddi Due To Cyp3a Inductionmentioning
confidence: 91%
“…Although 9 of 15, or 60%, of the clinical noninducers examined also activated PXR/CYP3A in DPX2 cells (Table 3), these same agents give induction of CYP3A4 mRNA in hepatocytes and other model systems . Among the noninducers, rosiglitazone promoted PXR activation in vitro only at concentrations exceeding 25 M, which far surpasses the C max of 1.4 M in vivo (Fahmi et al, 2008a), whereas omeprazole activated PXR at levels (Ͼ10 M) that exceeded the C max of 0.68 M (Soons et al, 1992). Despite eliciting substantial PXR activation (E max Ͼ9-fold), neither leflunomide nor omeprazole increased CYP3A-mediated luciferin-IPA metabolism in DPX2 cells (Fig.…”
Section: Dpx2 Cells For Predicting Ddi Due To Cyp3a Inductionmentioning
confidence: 91%
“…These probe drugs are moderate or high clearance drugs (Greenblatt et al, 1998;Wong et al, 1998;Lin, 2006), and the clearance and bioavailability are dependent on CYP3A4 metabolism. Omeprazole and nifedipine have not been found to induce CYP3A in vivo (Soons et al, 1992;Bowles et al, 1993). The correlation of AUC/F 2 values from CYP3A4 mRNA induction and the in vivo induction (Fig.…”
mentioning
confidence: 99%
“…tlj2) did not change. 20 In another study, a 14 d treatment with omeprazole (20 mg d-I ) caused an increase in AUC of carbamazepine in seven patients with duodenal ulcer.21 Similarly, a significant although small increase in digoxin AUCc-90 has been reported. The authors proposed a double mechanism to explain this interaction: an increase in absorption and a decrease in metabolism.…”
Section: Discussionmentioning
confidence: 93%